Literature DB >> 10877520

Treatment of early syphilis with azithromycin.

F Gruber1, M Kastelan, L Cabrijan, E Simonić, I Brajac.   

Abstract

An open, noncomparative study was performed to establish the efficacy of azithromycin in the treatment of early syphilis. Sixteen patients were treated with oral azithromycin: 1g the first day and then 500 mg for the following 8 days. Two patients were excluded from the study, leaving 14 patients for the evaluation of the efficacy. Venereal Disease Research Laboratory (VDRL) negativity was observed in 3 out of 6 patients treated for primary syphilis after 3 months and in all patients after 6 months. Two of 8 patients treated for manifest or early latent secondary syphilis had VDRL negativity after 3 months and 4 patients after 6 months. This study demonstrates that azithromycin is effective in the treatment of early syphilis. Two patients experienced gastrointestinal side effects which did not require treatment interruption.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10877520     DOI: 10.1179/joc.2000.12.3.240

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  5 in total

1.  Screening for syphilis infection: recommendation statement.

Authors:  Ned Calonge
Journal:  Ann Fam Med       Date:  2004 Jul-Aug       Impact factor: 5.166

Review 2.  Syphilis: using modern approaches to understand an old disease.

Authors:  Emily L Ho; Sheila A Lukehart
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

3.  [Syphilis treatment. German and international guidelines--a comparison].

Authors:  H Schöfer
Journal:  Hautarzt       Date:  2005-02       Impact factor: 0.751

Review 4.  Drug treatment of nonviral sexually transmitted diseases: specific issues in adolescents.

Authors:  C E Lehmann; F M Biro
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 5.  Management issues in syphilis.

Authors:  David Pao; Beng T Goh; James S Bingham
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.